Onward Medical N.V. Stock price

Equities

ONWD

NL0015000HT4

Medical Equipment, Supplies & Distribution

Real-time Euronext Bruxelles 12:35:12 2024-03-28 pm EDT 5-day change 1st Jan Change
4.78 EUR -0.21% Intraday chart for Onward Medical N.V. +1.49% +54.19%
Sales 2023 * 1.73M 1.87M Sales 2024 * 5.43M 5.85M Capitalization 144M 155M
Net income 2023 * -33M -35.56M Net income 2024 * -38M -40.95M EV / Sales 2023 * 80.9 x
Net cash position 2023 * 4.1M 4.42M Net Debt 2024 * 25.5M 27.48M EV / Sales 2024 * 31.2 x
P/E ratio 2023 *
-4.28 x
P/E ratio 2024 *
-3.83 x
Employees 96
Yield 2023 *
-
Yield 2024 *
-
Free-Float 61.6%
More Fundamentals * Assessed data
Dynamic Chart
Onward Medical Raises EUR20 Million Via Private, Public Offering of Shares MT
Onward Medical's Brain-computer Interface Technology Accepted Into US FDA Program MT
Onward Medical's ARC-BCI System Receives Breakthrough Designation MT
Onward Medical Begins Study of ARC-IM Therapy on Hemodynamic Instability Post Spinal Cord Injury MT
Onward Medical N.V. Announces Nature Medicine Publication Highlights Potential for ONWARD ARC Therapy to Improve Mobility After Parkinson's Disease CI
Swiss-designed technology helps Parkinson's patient walk again RE
Onward Medical N.V. Announces First-in-Human Implant of ARC-IM?? Stimulator with Brain-Computer Interface to Restore Arm, Hand, and Finger Function After Spinal Cord Injury CI
Onward Medical N.V. Announces CFO Changes CI
Onward Medical N.V. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Onward Medical Enters Two-year Distribution Deal With Lovell Government Services MT
Onward(R) Launches Partnership with Service-Disabled Veteran-Owned Business to Access U.S. Federal Health Market CI
Onward Medical N.V. Announces First-In-Human Use of Arc-Im(Tm) Lead to Restore Movement and Function After Spinal Cord Injury CI
Onward Medical N.V. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Onward Medical N.V. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Onward Medical's ARC-EX Platform Secures Breakthrough Device Designation Status from US FDA MT
More news
1 day-0.21%
1 week+1.49%
Current month+1.49%
1 month+8.64%
3 months+54.69%
6 months+13.00%
Current year+54.19%
More quotes
1 week
4.58
Extreme 4.58
5.16
1 month
4.56
Extreme 4.56
6.40
Current year
1.85
Extreme 1.85
6.58
1 year
1.85
Extreme 1.85
6.58
3 years
1.85
Extreme 1.85
13.28
5 years
1.85
Extreme 1.85
13.28
10 years
1.85
Extreme 1.85
13.28
More quotes
Managers TitleAgeSince
Founder - 14-11-30
Founder - -
Chief Executive Officer - 19-12-31
Members of the board TitleAgeSince
Director/Board Member 72 16-12-31
Chairman 67 16-04-18
Director/Board Member 54 16-04-18
More insiders
Date Price Change Volume
24-03-28 4.78 -0.21% 73,203
24-03-27 4.79 -1.24% 211,127
24-03-26 4.85 -3.77% 107,790
24-03-25 5.04 +1.82% 120,258
24-03-22 4.95 +5.10% 227,790

Real-time Euronext Bruxelles, March 28, 2024 at 12:35 pm EDT

More quotes
Onward Medical N.V. is a medical technology company developing and commercializing innovative therapies to enable functional recovery for people with spinal cord injury.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.78 EUR
Average target price
14.47 EUR
Spread / Average Target
+202.65%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Onward Medical N.V. - Euronext Bruxelles